You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2025

AbstractFullPdf
Nov 2021309308156
Dec 202114814873
Jan 2022919261
Feb 2022979764
Mar 202210010167
Apr 2022788146
May 202211411450
Jun 202210310550
Jul 2022899230
Aug 202210811061
Sep 202213213245
Oct 202210310344
Nov 2022595943
Dec 2022464526
Jan 2023384035
Feb 2023828240
Mar 2023495034
Apr 2023424235
May 2023505148
Jun 2023494936
Jul 2023505039
Aug 2023454529
Sep 2023666946
Oct 2023525239
Nov 2023626231
Dec 2023525242
Jan 2024515230
Feb 2024484837
Mar 2024585852
Apr 2024596141
May 2024585832
Jun 2024565640
Jul 2024535534
Aug 2024353526
Sep 2024404223
Oct 2024444534
Nov 2024424324
Dec 2024798130
Jan 2025363724
Feb 2025757625
Mar 2025676745
Apr 2025848565
May 2025454635
Jun 2025343433
Jul 2025110
Sep 2025110
Total318032121900